PTC Therapeutics | PTCT - Cash And Equivalent


PTC Therapeutics reported $833.99M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
Biogen USD 3.38B 374.2M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Cytokinetics USD 129.84M 7.32M Mar/2026
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Esperion Therapeutics USD 156.16M 11.69M Mar/2026
Gilead Sciences USD 7.56B 234M Dec/2025
Incyte USD 4.02B 435.22M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Ironwood Pharmaceuticals USD 220.47M 5.01M Mar/2026
Karyopharm Therapeutics USD 60.54M 22.87M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Pfizer USD 1.7B 561M Mar/2026
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
TG Therapeutics USD 442.21M 242.7M Mar/2026
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026
Xencor USD 14.17M 39.9M Mar/2026